CLYMClimb Bio, Inc. Common Stock — stock analysis & sentiment
Climb Bio, Inc. Common Stock (CLYM) last closed at $11.90, in the upper half of its 52-week range of $1.54–$14.42. Composite market sentiment across 1 analysis is positive (+37 on a −100 to +100 scale), as of Aug 3, 2026.
Produced by the Synoptiv Research Engine from public financial data. Read the methodology.
Go beyond the overview
The thesis, technical signals, risk levels, and complete evidence — everything the overview leaves out.
What the data says
An overview of the public data behind CLYM.
At $11.90, the stock sits near the upper end of a 52-week band that runs from $1.54 to $14.415 — a range in which the high is more than nine times the low. A spread that wide over a single year describes a stock that has repriced dramatically rather than drifted, and the current close leaves it closer to the top of that band than the bottom.
The market is valuing the business at roughly $681 million, or about 3.8 times book value. The forward price-to-earnings figure is negative at about -10.5, and the profit margin is zero, which together place the company in the pre-earnings category: the valuation rests on assets and expected outcomes rather than on profits currently being generated. Beta of 0.075 indicates the shares have moved almost independently of the broader market, which is consistent with a price driven by company- and program-specific developments more than by general market direction.
Recent news flow is light and largely procedural. Company-specific items cover investor conference appearances, inducement equity grants disclosed under Nasdaq listing rules, and data presentations at the American Society of Nephrology's Kidney Week in both 2024 and 2025. The most recent headline, from April 2026, is a third-party market forecast for idiopathic membranous nephropathy therapies rather than a company announcement — sector-level context rather than news about the company itself. Absent from the flow are trial readouts or regulatory milestones, so the recent record reflects disclosure and conference activity more than clinical events.
Written from public market data. Research, not financial advice — the thesis, signals and risk levels are in the full report.
Price chart
CLYM daily price history.
Market sentiment
A composite of the public market data in this analysis, from −100 (bearish) to +100 (bullish).
This gauge blends news tone, analyst views, insider and congressional activity, and price momentum into a single score. The full report breaks down each driver and pairs it with the thesis.
See the full sentiment breakdown in the report →Key stats
A public snapshot of commonly used market and valuation measures.
Valuation & size
- Market cap
- $681.43M
- Enterprise value
- $572.32M
- Forward P/E
- -10.51
- Price / book
- 3.84
Profitability & growth
- Net margin
- 0.00%
Price & risk
- Beta
- 0.08
- Average volume
- 1.23M
From noise to signal. The full report has CLYM’s thesis, trade signal, and risk levels.
About Climb Bio, Inc. Common Stock
Climb Bio is a clinical-stage biotechnology company developing treatments for immune-mediated diseases. Its lead candidate, budoprutug, is an anti-CD19 monoclonal antibody aimed at conditions driven by B cells; the company has advanced it into Phase 2 studies in primary membranous nephropathy and immune thrombocytopenia, and into a Phase 1b study in systemic lupus erythematosus. A second program, CLYM116, is a preclinical anti-APRIL monoclonal antibody directed at IgA nephropathy and other B-cell mediated conditions. The company was incorporated in 2018 and operated as Eliem Therapeutics before adopting the Climb Bio name in October 2024. It is headquartered in Wellesley Hills, Massachusetts.
Latest news
Recent headlines related to CLYM, with vendor tone.
CLYM — frequently asked questions
Answered from the public data on this page.
What is the current market sentiment for CLYM?
As of Aug 3, 2026, Climb Bio, Inc. Common Stock (CLYM) carries positive (+37 on a −100 to +100 scale) composite sentiment. The score fuses recent news tone, analyst recommendations, technical posture, insider and congressional activity, and market attention into a single figure. The full breakdown of each component is in the report.
How has CLYM stock been performing?
Climb Bio, Inc. Common Stock last closed at $11.90, in the upper half of its 52-week range of $1.54–$14.42.
What is CLYM's market cap and valuation?
Climb Bio, Inc. Common Stock has a market capitalization of about $681.43M.
What sector is CLYM in, and who are its competitors?
Climb Bio, Inc. Common Stock operates in the Healthcare sector, specifically Biotechnology.
Where can I find a full analysis of CLYM?
The full CLYM report covers the bull and bear cases, technical signals with entry, stop and target levels, complete financial statements, earnings history, insider and congressional trades, and the conditions that would invalidate the thesis. It requires a free account.
Analysis history
Every saved analysis, newest first.